Cargando…
Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
Individualized therapies targeting epidermal growth factor receptor (EGFR) mutations show promises for the treatment of non small-cell lung carcinoma (NSCLC). However, disease progression almost invariably occurs 1 year after tyrosine kinase inhibitor (TKI) treatment. The most prominent mechanism of...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
De Gruyter Open
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329801/ https://www.ncbi.nlm.nih.gov/pubmed/28352770 http://dx.doi.org/10.1515/med-2016-0014 |
_version_ | 1782511128692129792 |
---|---|
author | Wang, Yuli Guo, Zhitao Li, Yang Zhou, Qinghua |
author_facet | Wang, Yuli Guo, Zhitao Li, Yang Zhou, Qinghua |
author_sort | Wang, Yuli |
collection | PubMed |
description | Individualized therapies targeting epidermal growth factor receptor (EGFR) mutations show promises for the treatment of non small-cell lung carcinoma (NSCLC). However, disease progression almost invariably occurs 1 year after tyrosine kinase inhibitor (TKI) treatment. The most prominent mechanism of acquired resistance involves the secondary EGFR mutation, namely EGFR T790M, which accounts for 50%–60% of resistant tumors. A large amount of studies have focused on the development of effective strategies to treat TKI-resistant EGFR T790M mutation in lung tumors. Novel generations of EGFR inhibitors are producing encouraging results in patients with acquired resistance against EGFR T790M mutation. This review will summarize the novel inhibitors, which might overcome resistance against EGFR T790M mutation. |
format | Online Article Text |
id | pubmed-5329801 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | De Gruyter Open |
record_format | MEDLINE/PubMed |
spelling | pubmed-53298012017-03-28 Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma Wang, Yuli Guo, Zhitao Li, Yang Zhou, Qinghua Open Med (Wars) Review Article Individualized therapies targeting epidermal growth factor receptor (EGFR) mutations show promises for the treatment of non small-cell lung carcinoma (NSCLC). However, disease progression almost invariably occurs 1 year after tyrosine kinase inhibitor (TKI) treatment. The most prominent mechanism of acquired resistance involves the secondary EGFR mutation, namely EGFR T790M, which accounts for 50%–60% of resistant tumors. A large amount of studies have focused on the development of effective strategies to treat TKI-resistant EGFR T790M mutation in lung tumors. Novel generations of EGFR inhibitors are producing encouraging results in patients with acquired resistance against EGFR T790M mutation. This review will summarize the novel inhibitors, which might overcome resistance against EGFR T790M mutation. De Gruyter Open 2016-03-26 /pmc/articles/PMC5329801/ /pubmed/28352770 http://dx.doi.org/10.1515/med-2016-0014 Text en © 2016 Yuli Wang et al http://creativecommons.org/licenses/by-nc-nd/3.0 This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. |
spellingShingle | Review Article Wang, Yuli Guo, Zhitao Li, Yang Zhou, Qinghua Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma |
title | Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma |
title_full | Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma |
title_fullStr | Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma |
title_full_unstemmed | Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma |
title_short | Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma |
title_sort | development of epidermal growth factor receptor tyrosine kinase inhibitors against egfr t790m. mutation in non small-cell lung carcinoma |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329801/ https://www.ncbi.nlm.nih.gov/pubmed/28352770 http://dx.doi.org/10.1515/med-2016-0014 |
work_keys_str_mv | AT wangyuli developmentofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsagainstegfrt790mmutationinnonsmallcelllungcarcinoma AT guozhitao developmentofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsagainstegfrt790mmutationinnonsmallcelllungcarcinoma AT liyang developmentofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsagainstegfrt790mmutationinnonsmallcelllungcarcinoma AT zhouqinghua developmentofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsagainstegfrt790mmutationinnonsmallcelllungcarcinoma |